Good trade if you like short term day trading but if you bought at recent lows, it makes for a good long term hold and lower tax rate when finally sold.
Good advice, did exactly that, now hold 4,100 and have 7,400 profit in two weeks holding shares. Best start on a position I've had in a while. Thanks for your post!
chg47ady, I arrived on the scene on December 15th, just after you predicted this. On December 16th I opened a position and have added on dips each time. I now hold 4,100 shares, and have a nice $7,400 profit in two weeks. It is a core position for me, which I will hold long term, adding on dips as she goes. I really believe in the Company, the management, the products, and can't thank you and ozark580 enough for your contributions to my knowledge of all things OSIR an awesome company!
Sentiment: Strong Buy
Great ideas, already own MNKD, and IDRA, like the others as well. My adds to your list include SYN, OSIR in regenerative medicine going to be profitable in 2015 huge pipeline and two worldwide partnerships just signed Q4, NBS developmental biotech play, and SYN with MS drug Trimesta, ripe for partnership with TEVA on their patented product with Copaxone, just went off patent in April 2014, plus they have 3 other $1B drugs progressing through trials.
Good 're-read' on New Year's day as we evaluate where we stand and why we are here. Thanks MDR! All best to my investor friends in SYN for largess in your 2015 portfolio with a good chunk of it being invested right here!
Great article certainly ties the logic together for a partnership in the making between TEVA and SYN, while not a pump piece for either company (he does point out the risks of biotech and downside aspects if something goes wrong) the article comes across as both intelligent and evaluative. I would venture to say our stock gets a lift on January 2nd. FYI, last year on January 2nd we opened at 1.53, our high was 1.65, low 1.48, and we closed at 1.61. Then our 50-dma was 1.37 and 250-dma was 1.60. Now our 50-dma is 1.53 and our 250-dma is 1.89. Our high during the year was19 March, opened at 3.33, high 3.64, low 3.25, and close 3.45. There is no question we are a more valuable company now (with a great CEO in Riley) with cash of near 20 million, trials further along, partnership talks progressing, and yet we are priced 9% lower on 12-31 than we were on January 2, 2014. SYN is a screaming buy at these levels with exceptional risk reward.
Sold my position today, only 3,000 shares but the low confidence in management and a dropping share value were reasons for lack of confidence. I won't stay in an investment if there aren't compelling reasons, excluding buyout dreams, which rarely happen in this level of a company. Good luck, I only left $450 on the table, took the tax loss. Good luck longs, shorts, you won this round.
Every time when I see a stock like OSIR spike up and then retreat toward closing hours, it is just telling you where it's going the next day or week as the momentum continues. We are no where near buyer's exhaustion yet. This stock has legs, it is just being discovered, and the MDXG flap (subpoena filed Dec. 31, see their message board or here) will only serve to put our Company in the limelight. IMHO.
I bailed, it was one of my biggest tax losses of the year. It is still below the price where I sold, and I ain't coming back. Management doesn't deliver on it's promises, the wing it shareholder webcasts didn't inspire, especially the last one when they didn't get the NDA out as earlier scheduled. The stock sold off .14 or more the next couple of days, has added a few pennies since but there are way better places to risk your hard earned money. Those who have been here for years are in real low, so they're going to rally against a post like this. But new investors, I'd stay away.
It became one of my tax losses in 2014. Sad to say, but I had high hopes for my shares here, unfortunately for this investment, I had to offset some good investment gains and this position wasn't one of them. The management here may be good scientists but they know nothing of creating value for shareholders, there is no company identity that differentiates it from being part of the Russell Small cap index, which it followed most of the year except toward the end of the year when the index rallied and CUR stayed down. Very disappointing year for CUR shareholders.
I just looked at that BBEP chart, by definition, that is extremely oversold! It looks like it has just made the turn, you are on it, good eye, like that you know the Company and have made money there before. Good luck with that, if I loosen up some money that would be a good diversification for me.
I am turning 66 myself in February, decided to take my retirement SSI and leave my day job which was selling real estate. I had doubled my portfolio back in February at the height of the market, then saw it slowly/abruptly erode, and now heading back up. I ended the year up just over 30% not counting the money I took out, which would put me in high 30's on a percentage basis. I appreciate your story, hearing of your trades etc, thanks for sharing this about yourself. Jr.
Script growth rate since average run rate of 2nd quarter is 205%! We had 10,299 scripts total for the entire 2nd Quarter, which had 13 weeks. Divide 10,299 by 13 weeks gives you an average weekly script volume of 792. The week ending 12/19 we had 1,624, which is 205% of 792 just 6 months later. Projecting this growth rate to an annual growth rate (simple not compounded just double it) is 410% annual growth rate. This may point to total scripts in 2015 of 354,681. What is the value of a script to Company? Anyone want to take a stab at when this company goes profitable?
Their stock is down AH lowest trade 10.22, last trade 10.46, down 9.28%. Guess the shareholders who got the news decided to avoid a sell off on Monday morning. We may get a slight bounce off this, but it would be hard to measure if we have organic growth in our share price due to being a HOT stock right now.
MARIETTA, Ga. , Dec. 31, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received a subpoena from the Office of Inspector General ("OIG") of the Department of Health and Human Services ("HHS") in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.
MiMedx intends to cooperate fully with the government in its investigation, and the Company will attempt to expedite the process. MiMedx has already begun the process of producing the responsive documents. To the Company's knowledge, no proceedings have been initiated at this time. The Company cannot predict whether any proceeding might be initiated.
Parker H. Petit , Chairman and CEO, said, "I can assure you that the corporate officers at MiMedx are not aware of anything that would stimulate this investigation. We have continually maintained and improved a robust compliance program. We have been very focused on the thoroughness of our compliance policies and our staff adhering to those policies. For instance, MiMedx employees participate in a thorough training program regarding our policies and the standards that have been established and enforced to assure their understanding and adherence to our compliance programs. Employees may convey anonymously and directly to senior management and our Board of Directors any form of concern, complaint or inquiry related to our compliance programs or other issues. With the significant growth we are experiencing, this has been and continues to be an initiative in which we devote considerable time, attention and resources."
Petit continued, "We are aware of investigations in the wound care market over the past several years, in particular, the ongoing investigation into the sales and marketing practices of Advanced BioHealing ("ABH"), the original manufacturer of Dermagraft®. We anticipated that the ABH investigation could lead to a review of other industry participants, particularly in view of the fact that several industry participants, including MiMedx and some of our competitors, have hired former ABH employees. We screen all of our applicants very carefully. With respect to former ABH applicants, we sought additional input from some former ABH corporate management who joined MiMedx and who were familiar with the suspected violations and the individuals involved. Approximately 18 months ago, we had confirmation of a violation of our compliance policies, and within 24 hours, that individual was terminated."
Petit concluded, "We expect this investigation will confirm that our policies and procedures are working as intended. If any issues are uncovered, we will certainly address them promptly and take steps to ensure future compliance."
On Friday, January 2, 2015 , beginning at 10:30 a.m. Eastern Standard Time , MiMedx management will host a live broadcast of its conference call with shareholders to present prepared remarks and respond to questions regarding its receipt of the civil subpoena.
Thanks dawg for weighing in, what do you think about that last 16,400 shares at 1.46...who is doing that and why?
Most of the day down 1.42 and then 1.41, until it closes and 16,400 shares were bought at 1.46. Somebody (who is the angel investor?) is wanting this to close higher, and is willing to pay more to see the end of year at 1.46. I do think there was downward pressure on the stock from tax selling, right up to the last trades. Now that this is behind us, we should trade more honestly in January. Anyone have any other explanation or logic to this?
The sentiment and stock price will likely shift in January. You must have ridden this over ADCOMM and PDUFA to find yourself deeply disappointed. Sorry for your dilemma, but seeing your ID name makes me think you will hold this until the ship comes in, I hope you don't bail now, sentiment and pps are surely going up from here. I added shares today at 5.16 and 5.30, but hold my average at 5.47, within spitting distance of breakeven. I've been there, held many through the red days, one of my biggest was IDRA which now is soaring, but I had a big paper loss earlier this year and held through it, adding all the way. Good luck, you will be fine unless you bail now.
Hey Tappy, thanks and best wishes to you as well. I am a small holder here, been a good year all considered, and yet I will always remember you and our posts back and forth. I chose to depart from here before I got hurt, overall made good money here, not great though, wasn't so good at timing my exits, not nearly so good as Wotten, that louse! Anyway, thanks for showing up again, check out my best pick for Andre's contest in 2015, OSIR, up $2.00 per share since I started buying it a little over two weeks ago. Have a great 2015 Tappy!